SUN PHARMACEUTICAL INDUSTRIES
|
SUN PHARMACEUTICAL INDUSTRIES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 47.84 | 45.55 | 39.91 | 35.32 | 13.64 |
| CEPS(Rs) | 60.44 | 56.50 | 50.87 | 46.22 | 23.13 |
| DPS(Rs) | 16.00 | 16.00 | 13.50 | 11.50 | 10.00 |
| Book NAV/Share(Rs) | 348.31 | 301.00 | 265.36 | 233.38 | 200.11 |
| Tax Rate(%) | 23.51 | 20.16 | 12.98 | 9.01 | 24.00 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 28.21 | 28.69 | 26.29 | 26.40 | 14.71 |
| EBIT Margin(%) | 26.44 | 26.60 | 23.35 | 21.83 | 6.86 |
| Pre Tax Margin(%) | 25.86 | 26.16 | 22.86 | 21.44 | 6.67 |
| PAT Margin (%) | 19.78 | 20.88 | 19.89 | 19.51 | 5.07 |
| Cash Profit Margin (%) | 24.81 | 25.78 | 25.17 | 25.27 | 8.26 |
| Performance Ratios | |||||
| ROA(%) | 12.02 | 12.99 | 12.17 | 11.87 | 5.20 |
| ROE(%) | 14.85 | 16.16 | 16.13 | 16.46 | 7.21 |
| ROCE(%) | 19.11 | 19.89 | 17.60 | 17.24 | 9.28 |
| Asset Turnover(x) | 0.61 | 0.62 | 0.61 | 0.61 | 1.03 |
| Sales/Fixed Asset(x) | 1.10 | 1.16 | 1.11 | 1.07 | 1.81 |
| Working Capital/Sales(x) | 1.42 | 1.53 | 1.83 | 2.20 | 3.81 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.91 | 0.86 | 0.90 | 0.93 | 0.55 |
| Receivable days | 89.14 | 84.33 | 85.38 | 91.17 | 53.09 |
| Inventory Days | 67.85 | 69.81 | 76.70 | 80.83 | 48.68 |
| Payable days | 213.72 | 201.01 | 194.01 | 174.10 | 149.21 |
| Valuation Parameters | |||||
| PER(x) | 36.73 | 38.10 | 40.60 | 27.84 | 67.07 |
| PCE(x) | 29.07 | 30.72 | 31.86 | 21.27 | 39.55 |
| Price/Book(x) | 5.05 | 5.77 | 6.11 | 4.21 | 4.57 |
| Yield(%) | 0.91 | 0.92 | 0.83 | 1.17 | 1.09 |
| EV/Net Sales(x) | 7.08 | 7.74 | 7.86 | 5.38 | 5.57 |
| EV/Core EBITDA(x) | 21.02 | 23.61 | 26.51 | 19.24 | 19.03 |
| EV/EBIT(x) | 26.79 | 29.10 | 33.65 | 24.67 | 46.73 |
| EV/CE(x) | 4.72 | 5.49 | 5.73 | 3.80 | 3.22 |
| M Cap / Sales | 7.21 | 7.92 | 8.02 | 5.37 | 5.68 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.19 | 8.42 | 10.51 | 13.53 | 15.39 |
| Core EBITDA Growth(%) | 14.31 | 19.89 | 17.07 | 8.50 | 21.36 |
| EBIT Growth(%) | 10.54 | 23.46 | 18.22 | 107.88 | 56.71 |
| PAT Growth(%) | 5.32 | 13.80 | 12.70 | 151.36 | 49.07 |
| EPS Growth(%) | 5.04 | 14.13 | 13.01 | 158.91 | 12.70 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.05 | 0.03 | 0.04 | 0.11 | 0.02 |
| Current Ratio(x) | 2.82 | 2.89 | 2.56 | 2.00 | 2.03 |
| Quick Ratio(x) | 2.31 | 2.33 | 1.98 | 1.47 | 1.51 |
| Interest Cover(x) | 45.61 | 60.44 | 47.50 | 55.70 | 36.19 |
| Total Debt/Mcap(x) | 0.01 | - | 0.01 | 0.03 | - |
Compare Financial Ratios of peers of SUN PHARMACEUTICAL INDUSTRIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| SUN PHARMACEUTICAL INDUSTRIES | ₹426,115.7 Cr | 0.8% | -2.1% | 4.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹266,424.0 Cr | 4.9% | 7.9% | 54.7% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹179,914.0 Cr | 1.6% | -2.7% | 28.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹114,599.0 Cr | 2.6% | 14.2% | 3.9% | Stock Analytics | |
| CIPLA | ₹113,112.0 Cr | 2.4% | 3.4% | -12% | Stock Analytics | |
| MANKIND PHARMA | ₹104,631.0 Cr | -0.3% | -2% | 2.9% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUN PHARMACEUTICAL INDUSTRIES | 0.8% |
-2.1% |
4.8% |
| SENSEX | 5.5% |
7.5% |
-8.7% |
You may also like the below Video Courses
